Guideline Recommendations for Primary and Secondary Prophylaxis of Chemotherapy‑Induced Neutropenia

Risk Assessment

High‑risk chemotherapy regimens (≥20 % febrile neutropenia risk) – include dose‑dense AC, TAC, FEC100 for breast cancer and FOLFIRINOX for pancreatic cancer; patients receiving these regimens should receive primary G‑CSF prophylaxis. [NCCN] [1][2]
Intermediate‑risk regimens (10–20 % FN risk) – such as docetaxel‑based schedules for breast cancer and FOLFOX for colorectal cancer; prophylaxis is indicated when additional patient‑specific risk factors are present. [NCCN] 2
Patient‑specific risk factors that elevate overall FN risk – age ≥ 65 years (most important), poor performance status, prior FN episode, extensive prior chemotherapy or large radiation fields, bone‑marrow involvement, renal or hepatic dysfunction, poor nutritional status, open wounds/active infection, recent surgery, and advanced cancer with serious comorbidities. Presence of any of these factors upgrades an intermediate‑risk regimen to a prophylaxis indication. [ASCO] [3][4][5][2][6][7]

Mandatory G‑CSF prophylaxis for any chemotherapy regimen with >20 % FN risk, for dose‑dense protocols, and for intermediate‑risk regimens when ≥1 patient risk factor is present. [ASCO] [3][4]6
Curative or adjuvant intent where dose reductions would jeopardize survival also mandates primary prophylaxis. [ASCO] [3][1]
Regimens with <10 % FN risk may still require G‑CSF when multiple high‑risk patient factors coexist and the treatment is curative with potential for serious outcomes. [NCCN] [8][9]

Pegfilgrastim should not be used with weekly chemotherapy schedules or with FOLFOX regimens, and its benefit is unproven for regimens administered at intervals shorter than two weeks. [NCCN] [8][9]
Therapeutic G‑CSF (febrile neutropenia) – only filgrastim or sargramostim are recommended; pegfilgrastim is not advised because dosing cannot be adjusted in the acute setting. [NCCN] [8][9]

Mandatory secondary G‑CSF prophylaxis for patients who experienced febrile neutropenia or dose‑limiting neutropenic events in a prior cycle when dose reduction would compromise disease‑free or overall survival. [ASCO] [3][6]7

Do not use G‑CSF routinely as an adjunct to antibiotics for febrile neutropenia. [ASCO] [3][6]7
Consider therapeutic G‑CSF in febrile neutropenic patients with any of the following high‑risk features:
- Expected neutropenia ≥10 days or profound neutropenia (ANC ≤ 0.1 × 10⁹/L)
- Age > 65 years
- Uncontrolled primary disease, pneumonia, hypotension/multi‑organ dysfunction (sepsis), invasive fungal infection, or hospitalization at fever onset.
- (All above) – evidence supports selective use of filgrastim or sargramostim. [ASCO] [3][1]6

Avoid pegfilgrastim with weekly chemotherapy or FOLFOX regimens and avoid its therapeutic use for established febrile neutropenia. [NCCN] [8][9]
Age > 65 years alone should trigger primary prophylaxis for intermediate‑risk regimens. [NCCN] [4][5]

Primary G‑CSF prophylaxis reduces the incidence of febrile neutropenia episodes. [ASCO] 1
It also shortens the duration of antibiotic therapy required for neutropenic infections. [NCCN] 8

The National Comprehensive Cancer Network recommends that chemotherapy regimens with a risk of febrile neutropenia >20% are considered high-risk, while those with 10-20% risk are intermediate-risk, and those with <10% risk are low-risk 10, 11, 12
ALL induction regimens are considered high-risk for febrile neutropenia 10
Non-Hodgkin's Lymphomas regimens such as CFAR, ICE, RICE, CHOP-14 ± rituximab, MINE, DHAP, ESHAP, and HyperCVAD + rituximab are considered high-risk for febrile neutropenia 10, 12
Breast Cancer regimens such as docetaxel + trastuzumab, dose-dense AC followed by T, and TAC are considered high-risk for febrile neutropenia 10, 12, 13
Bladder Cancer regimen MVAC is considered high-risk for febrile neutropenia 10, 12
Melanoma regimen dacarbazine-based combinations is considered high-risk for febrile neutropenia 10
Pancreatic Cancer regimen FOLFIRINOX is considered high-risk for febrile neutropenia 14
Gastric Cancer regimen DCF is considered high-risk for febrile neutropenia 12

Breast Cancer regimens such as docetaxel every 21 days, CMF classic, AC + sequential docetaxel, FEC + sequential docetaxel, and paclitaxel every 21 days are considered intermediate-risk for febrile neutropenia 15, 16
Colorectal Cancer regimen FOLFOX is considered intermediate-risk for febrile neutropenia 15, 16
Non-Hodgkin's Lymphomas regimen EPOCH for AIDS-related NHL is considered intermediate-risk for febrile neutropenia 15, 16

Age ≥65 years is a risk factor for febrile neutropenia 17, 13
Previous chemotherapy or radiation therapy is a risk factor for febrile neutropenia 17
Preexisting neutropenia or bone marrow involvement with tumor is a risk factor for febrile neutropenia 17
Poor performance status is a risk factor for febrile neutropenia 17
Poor renal function is a risk factor for febrile neutropenia 17
Liver dysfunction, especially elevated bilirubin, is a risk factor for febrile neutropenia 17
Recent surgery is a risk factor for febrile neutropenia 17
Infection/open wounds is a risk factor for febrile neutropenia 17

The National Comprehensive Cancer Network recommends primary prophylaxis with G-CSF for high-risk regimens (>20% risk of febrile neutropenia) 10, 11
For intermediate-risk regimens (10-20% risk of febrile neutropenia), evaluate patient risk factors and consider G-CSF prophylaxis if ≥1 risk factors are present 11, 18
G-CSF administration guidelines include starting 24-72 hours after completion of chemotherapy and continuing until post-nadir ANC recovery for daily G-CSFs, and a single 6 mg dose per cycle for long-acting G-CSFs 18, 19